whitepaper

Application note: CRISPR-Cas9 screening for target identification

Posted: 29 May 2020 | | No comments yet

The identification and validation of novel drug targets is a challenging process for drug discovery programmes.

Forward genetic screening with the RNA-guided nuclease Cas9 provides a new and powerful tool to interrogate gene function at a genome-wide level. In contrast to RNAi technology, which can be prone to off-target effects and variable knockdown efficiencies, the combination of bacterial CRISPR (clustered regularly interspaced short palindromic repeat)-associated Cas9 nuclease and pooled short guide RNA (sgRNA) libraries aims to generate complete knockouts with high on-target specificity. We have adapted a pooled-based screening protocol, where lentivirus transduction delivers both the Cas9 endonuclease and the sgRNA to the cells.











    To read this application note in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


    *

    *

    *

    *

    *

    *

    *

    *

    This content is provided to you for free thanks to the kind support of our sponsor: Horizon Discovery

    Related organisations

    Send this to a friend